For investors analyzing ormp stock (Oramed Pharmaceuticals), the company's financial profile can initially seem like a paradox. Currently trading around $4.00 per share with a market capitalization of approximately $163 million, ormp stock boasts an incredibly low price-to-earnings (P/E) ratio of roughly 1.5x. However, this statistical anomaly hides a complex narrative of a massive corporate transformation. Following the high-profile failure of its Phase 3 oral insulin trial, Oramed has pivoted from a pure-play clinical developer into an active, diversified medical technology holding company. This guide explores the details of Oramed's major strategic transactions, its financial health, and whether this unique biotech structure makes the stock a compelling buy in today's market.

The Phase 3 Setback and the Refined Oral Insulin Pipeline

To understand the current state of ormp stock, one must first look at the defining clinical event in Oramed's history. For years, Oramed's primary value driver was ORMD-0801, a highly anticipated oral insulin capsule designed to treat patients with Type 2 Diabetes (T2D). The company's proprietary Protein Oral Delivery (POD) technology was engineered to overcome the two main hurdles of oral peptide administration: enzymatic degradation in the gastrointestinal tract and poor absorption across the intestinal wall. By combining protease inhibitors with absorption enhancers in an enteric-coated capsule, the POD platform is designed to release insulin in the small intestine, allowing it to be absorbed directly into the portal vein. This mimics the natural physiological pathway of endogenous insulin, delivering it first to the liver (known as "first-pass" hepatic metabolism) and reducing the systemic side effects associated with traditional subcutaneous injections.

However, in January 2023, Oramed announced that its Phase 3 ORA-D-013-1 trial failed to meet its primary endpoint of improving glycemic control (measured by HbA1c) compared to a placebo over a 26-week period. The devastating clinical failure led to a massive sell-off of ormp stock, decimating its valuation and forcing management to re-evaluate the company's direction.

Rather than abandoning the asset, Oramed's scientific team conducted an exhaustive post-hoc analysis of its massive Phase 2 and Phase 3 clinical databases. Their research yielded a critical breakthrough: they identified highly encouraging "high-responder" subgroups. Specifically, participants with lower Body Mass Index (BMI) and older demographics showed a clinically meaningful reduction in HbA1c of over 1.0% when taking ORMD-0801. Armed with this data, Oramed refined its target patient criteria and is currently initiating a focused, 60-patient, US-based clinical trial to validate these findings. By utilizing a highly targeted, smaller, and adequately powered cohort, Oramed is taking a capital-efficient path to generate clinical validation, minimizing operational cash burn while keeping the long-term clinical upside of its oral insulin program alive.

It is also worth noting that Oramed initially sought to offload the costs of this clinical development through a joint venture with Hefei Tianhui Biotech (HTIT) in early 2025. The planned joint venture, named OraTech Pharmaceuticals, was structured to advance oral insulin globally and was expected to list on the Nasdaq. However, in October 2025, Oramed officially terminated the agreement because HTIT was unable to satisfy the required financial closing conditions. This termination ultimately allowed Oramed to retain 100% independent ownership of its POD platform and intellectual property, positioning the company to execute a far more lucrative transaction just a few months later.

The Landmark January 2026 Lifeward Transaction

On January 13, 2026, Oramed announced the signing of a binding agreement for a transformative strategic transaction with Lifeward Ltd. (NASDAQ: LFWD, formerly known as ReWalk Robotics). This transaction completely reshaped the operational structure of both companies, transferring Oramed's POD oral drug delivery platform to Lifeward.

Under the terms of the agreement, Oramed transferred its POD platform intellectual property to Lifeward. In exchange, Oramed received up to a 49.9% beneficial equity ownership stake in Lifeward. Additionally, the transaction was structured as a multi-stage capital commitment to bring Lifeward toward profitability:

• Convertible Notes: Lifeward issued $10 million in senior secured convertible notes in a private placement, of which Oramed invested $9 million.
• Milestone Notes: An additional milestone-based $10 million senior secured convertible note was structured, with Oramed committing another $9 million. Both tranches of notes carry 100% warrant coverage.
• Total Commitment: The overall capital framework provides Lifeward with access to up to approximately $47 million of capital through equity, convertible notes, milestone-based funding, and warrants.

To ensure Lifeward remains focused on its path to profitability, the two companies entered into a clinical trial management agreement. Under this agreement, Oramed retains the responsibility for managing and funding the clinical development of the POD platform. This represents a brilliant operational compromise: Lifeward is insulated from the immediate cash burn of running clinical trials, while Oramed retains exposure to the immense clinical upside of oral insulin and other oral biological therapies through its 49.9% equity stake in the combined entity.

Lifeward is a commercial-stage medical technology company that design, manufactures, and markets innovative solutions that transform the lives of individuals with physical limitations or disabilities. Its flagship products include the ReWalk Personal Exoskeleton (an FDA-cleared, motorized device that enables individuals with spinal cord injuries to stand and walk) and the AlterG Anti-Gravity Treadmill (which uses differential air pressure to reduce impact during rehabilitation). Over the four quarters preceding the transaction, Lifeward's commercial products generated a robust $26 million in revenue.

By uniting Lifeward's commercial-stage medical robotics business with Oramed's high-upside biotech delivery platform, the transaction created a highly diversified biomedical company. Furthermore, Lifeward is led by CEO Mark Grant, a highly experienced medical executive with over 25 years of industry experience at giants like Medtronic and Bristol Myers Squibb. Grant's deep background in the diabetes sector makes him uniquely qualified to drive the commercial expansion of Lifeward's robotic portfolio while overseeing the strategic evolution of the POD platform.

The Investment Engine: Scilex, Alpha Tau, and the Financial Balance Sheet

Oramed's corporate transformation is not limited to the Lifeward deal. Over the past three years, Oramed has increasingly operated like a specialized biotech venture capital firm, leveraging its capital reserves to build a highly lucrative, diversified investment portfolio.

The Scilex Windfall and the $0.25 Special Dividend

Oramed's most successful investment to date has been its strategic transaction with Scilex Holding Company (NASDAQ: SCLX), a developer of non-opioid pain management therapeutics. Oramed initially provided Scilex with a massive $99.5 million senior secured loan in 2023.

On January 7, 2026, Oramed announced that it had received an $18 million cash payment from Scilex, representing the full satisfaction of Scilex's obligations under their initial Option Agreement. This cash inflow brought Oramed's total realized returns on its original $99.5 million Scilex investment to an impressive $118 million. Despite this successful partial exit, Oramed continues to hold a massive ongoing stake in Scilex's future success, which includes:

• A $27 million outstanding note from Scilex.
• A $12 million convertible note (convertible at Oramed's option into Scilex equity at $36 per share, or repayable in quarterly cash installments through October 2026).
• A substantial warrant position.
• A nine-year royalty interest in Scilex's marketed and pipeline products.

In a rare and highly shareholder-friendly move for a micro-cap biotech, Oramed's Board of Directors approved a one-time special cash dividend of $0.25 per share. The dividend, which resulted in an aggregate distribution of approximately $10.5 million, was funded entirely from the surplus cash generated by the Scilex returns and paid to shareholders on January 26, 2026.

Other Core Investments

In addition to Scilex, Oramed maintains several other key high-conviction positions across the biomedical landscape:

• Alpha Tau Medical (NASDAQ: DRTS): In April 2025, Oramed executed a $36.9 million strategic investment and collaboration with Alpha Tau, a pioneer in localized cancer radiation therapies. Alpha Tau's breakthrough technology, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), recently achieved a massive milestone by obtaining Shonin marketing approval in Japan and is currently advancing through multiple late-stage clinical trials in the US across four distinct oncology indications.
• Pelthos Therapeutics: On May 19, 2026, Oramed's Q1 10-Q SEC filing revealed that the company liquidated its remaining equity position in Pelthos for net proceeds of $3.45 million, securing another liquid cash return to bolster its balance sheet.

Deconstructing the Q1 2026 Financial Statements

To understand why ormp stock is currently trading at such a deeply discounted valuation on traditional stock screeners, one must dive into the company's Q1 2026 financial report, which was filed on May 19, 2026.

During the first quarter of 2026, Oramed reported $0 in product or licensing revenue, down from $2.0 million in Q1 2025. This decline was expected, as prior license-related revenues had been fully recognized and the company has transitioned away from direct product sales.

However, despite recording $0 in operating revenue, Oramed reported a massive net income of $38.31 million (or $0.91 per diluted share), representing a stunning swing from the net loss of $7.64 million (or -$0.19 per share) recorded in Q1 2025.

This massive profit was not driven by operational success, but rather by fair value accounting adjustments. Under GAAP rules, Oramed must mark its equity investments in publicly traded companies (such as Alpha Tau and Scilex) to market value at the end of each quarter. Because these stocks experienced significant appreciation during the quarter, Oramed recorded large unrealized paper gains on its income statement. Conversely, Oramed still recorded an operational operating loss of $3.7 million for the quarter, reflecting the ongoing expenses associated with its clinical development programs and corporate administration.

The Balance Sheet Breakdown

Oramed's balance sheet remains exceptionally strong and liquid, consisting of the following key figures as of March 31, 2026:

• Cash and Cash Equivalents: $13.2 million.
• Short-Term Investments: $52.64 million.
• Long-Term Investments: $199.4 million (representing the market value of its holdings in Lifeward, Alpha Tau, and Scilex).
• Total Assets: $268.85 million.
• Total Liabilities: Just $30.57 million (including $10.56 million in current liabilities and $20.01 million in long-term liabilities).

Oramed's net cash position fell from $45.95 million at the end of 2025 to $13.2 million by March 31, 2026. This decline was primarily driven by the cash outflows required for the $10.5 million special dividend and the initial $9.0 million strategic investment in Lifeward's senior secured convertible notes.

The Investment Thesis: Weighing the Risks and Rewards of ORMP Stock

For value-oriented and biotech investors, ormp stock presents a highly unique risk-reward profile. Below, we break down the core arguments for and against investing in Oramed at its current valuation.

The Bull Case

1. Massive Discount to Net Asset Value (NAV): At a current share price of ~$4.00, Oramed's market capitalization stands at roughly $163 million. However, its total assets minus liabilities (book value) is close to $238 million—or roughly $5.80 per share. Investors are effectively buying Oramed at a steep 30%+ discount to the liquidation value of its public holdings, meaning they are getting the refined oral insulin trial and the POD intellectual property entirely for free.
2. De-Risked Portfolio Approach: Traditional micro-cap biotechs carry immense binary risk; a single clinical trial failure can wipe out 90% of a company's value overnight. By transitioning into a biomedical holding company, Oramed has diversified its risk across medical robotics (Lifeward), cancer radiation therapy (Alpha Tau), and non-opioid pain management (Scilex).
3. Lucrative Passive Income Potential: Oramed's nine-year royalty interest on Scilex's commercial product portfolio and its potential future royalty stream from Lifeward's commercialization of the POD platform could provide highly lucrative, recurring revenue that is completely decoupled from Oramed's own operational expenses.

The Bear Case

1. Limited Cash Runway for Core Operations: While Oramed has massive long-term assets, its direct liquid cash of $13.2 million is relatively small. In its May 2026 10-Q filing, the company specifically noted that its current cash reserves are only sufficient to fund its operations for at least the next 12 months. To fund ongoing clinical development of the POD platform, Oramed may eventually be forced to liquidate some of its prize investments (such as its Scilex notes or Alpha Tau shares) or dilute its shareholders.
2. Exposure to Volatile Micro-Caps: Oramed's reported net income and book value are highly sensitive to the stock prices of Lifeward (LFWD), Alpha Tau (DRTS), and Scilex (SCLX). Because these are highly volatile, relatively low-liquidity micro-cap stocks, any broad market downturn or regulatory setback at these companies would decimate Oramed's asset value and swing its reported earnings deeply into the red.
3. R&D Drag: Oramed remains contractually responsible for funding and managing the clinical trials of the POD platform. Clinical trials are notoriously expensive, and any delays or design changes in the refined oral insulin trial could accelerate the company's cash burn.

FAQ Section

Is ORMP stock a good investment?

ORMP stock is highly appealing to risk-tolerant, value-oriented investors who want exposure to biomedical innovation without the extreme binary risk of a single-drug pipeline. Because the stock trades at a steep discount to its net asset value, it offers a strong margin of safety. However, the company is operationally unprofitable and highly dependent on the market performance of its portfolio holdings.

What happened to Oramed's oral insulin program?

After its Phase 3 trial failed in January 2023, Oramed analyzed the data and discovered a highly responsive subgroup of patients (lower-BMI and older demographics) where the drug achieved clinically meaningful HbA1c reductions. Oramed is currently launching a focused, 60-patient US trial to validate these results. Additionally, Oramed transferred the underlying POD platform to Lifeward in January 2026 in exchange for a 49.9% equity stake, ensuring the technology will also be developed for other high-value peptide and protein therapies.

Does ORMP stock pay a dividend?

Oramed does not pay a regular, recurring dividend. However, following the highly successful partial liquidation of its Scilex investment, Oramed paid a special cash dividend of $0.25 per share on January 26, 2026. Future special dividends are possible but remain dependent on the company generating excess capital from its investment exits.

What is the relationship between Oramed and Lifeward?

In January 2026, Oramed entered into a landmark strategic partnership with Lifeward. Oramed transferred its POD platform intellectual property to Lifeward in exchange for up to a 49.9% beneficial equity stake in Lifeward. Oramed also committed up to $18 million in convertible notes to support Lifeward's commercial path to profitability, while retaining responsibility for managing and funding the POD clinical development.

Conclusion

Oramed Pharmaceuticals (NASDAQ: ORMP) has pulled off one of the most intriguing pivots in the micro-cap biotech sector. By transitioning from a single-asset developer to a diversified holding company, Oramed has protected its balance sheet, rewarded shareholders with a special dividend, and secured a massive stake in a revenue-generating medical robotics company. While investors must monitor the company's 12-month operational cash runway and the stock volatility of its portfolio holdings, ormp stock presents a highly compelling value proposition, trading at a deep discount to its net asset value of over $5.80 per share.